What exactly did Oppenheimer do on March 02, 2026 regarding URGN analyst rating?

On March 02, 2026 Oppenheimer reiterated an **Outperform** rating on UroGen Pharma Ltd. (URGN). The firm kept its view unchanged and did not publish a new price target in the public summary.

Does the maintained rating include a new URGN price target?

No. Oppenheimer maintained the Outperform rating but the public note did not announce a new URGN price target. Investors should monitor follow-up research notes for any target updates.

How should investors interpret this URGN analyst rating in their portfolio?

A maintained Outperform suggests continued analyst confidence but not added conviction. Use the URGN analyst rating alongside company results, pipeline milestones, and cash metrics before changing positions.

What is Meyka AI’s stance on this maintained rating and URGN’s longer-term outlook?

Meyka AI rates URGN with a grade of B+. We view the maintained Outperform as supportive for medium-term upside, but recommend investors pair this URGN analyst rating with operational updates and risk management.

Analyst Ratings

Oppenheimer Maintains Outperform on UroGen Pharma Ltd. (URGN) March 2026

ByHuzaifa Zahoor March 3, 2026

Oppenheimer maintained an Outperform rating on UroGen Pharma Ltd. (URGN) on March 02, 2026, a clear signal in the current URGN analyst rating mix. The firm described its stance as “We Buy the Weakness” while leaving the rating unchanged, after the stock moved -4.57% ($-0.91) ahead of the announcement. This maintained rating shows continued analyst support amid recent operational updates and a market cap of $890,305,126.